Symposium Home Page
Inaugural Brain Cancer Symposium
September 30 – October 1, 2022
Ann Arbor, MI
The BioInnovations in Brain Cancer’s inaugural symposium is bringing together scientists to bridge the gap between brain cancer biology research and novel technological developments in order to advance the diagnosis and treatment of glioma to improve the lives of patients.
The symposium will take place at the University of Michigan – Ann Arbor Campus over two days on September 30th and October 1st.
Important Dates and Information:
Early bird reduced registration pricing ends July 15, 2022
The abstract submission preferred deadline has been extended to July 17, 2022
Registration deadline is September 21, 2022
The University of Michigan has specific Covid-19 mitigation guidelines that must be followed for individuals visiting the campus. Please visit our Community and Visitors Webpage to learn more.
Register and Submit an Abstract TodaySymposium Information
Click on the tiles to find out more information on symposium registration, hotel details, speakers and more.
Event Organization
Learn more about our BIBC program, the Symposium Organizers, Sponsorship, and the city of Ann Arbor
Invited Speakers
Keynote Speakers
Steven Kalkanis, MD, CEO of the Henry Ford Medical Group (HFMG) and Senior Vice President and Chief Academic Officer of Henry Ford Health System
Justin Hanes, PhD, Director, Center for Nanomedicine, Lewis J. Ort Professor of Ophthalmology at Johns Hopkins Medicine
Confirmed Symposium Speakers
Peter Fecci, MD, PhD, Duke University
Dolores Hambardzumyan, PhD, MBA, Icahn School of Medicine at Mount Sinai
Shawn Hervey-Jumper, MD, University of California San Francisco
Irina Balyasnikova, PhD, Northwestern University
Ali Shilatifard, PhD, Northwestern University
Ranjit Bindra, MD, PhD, Yale
Yon Son Betty Kim, MD, PhD, MD Anderson Cancer Center
Robert Prins, PhD, University of California Los Angeles
Shawn Hingtgen, PhD, University of North Carolina
Roland Friedel, PhD, Icahn School of Medicine at Mount Sinai
Balveen Kaur, PhD, Georgia Cancer Center at Augusta University
David Reardon, MD, Dana-Farber Cancer Institute and Harvard Medical School
Hong Chen, PhD, Washington University in St. Louis
Ananth V. Annapragada, PhD, Texas Children’s Hospital
Jose Javier Bravo-Cordero, PhD, Icahn School of Medicine at Mount Sinai
Robert G. Thorne, PhD, Denali Therapeutics and University of Minnesota – Minneapolis
Kannan Rangaramanujam, PhD, MS, Johns Hopkins Medicine
Natalie Artzi, PhD, Wyss Institute and Harvard Medical School